Woman's Hour
What influence can a first lady have on world affairs?
Related Stories
Sources: Miss. State QB Taylor facing surgery, to miss rest of season
Mississippi State quarterback Kamario Taylor, college football's breakout star this season, is facing season-ending surgery on his injured toe, sources told ESPN on Tuesday. He will miss the rest of the season and is expected to make a full recovery, sources told ESPN. Taylor has an appointment Tuesday to get his toe checked out by a specialist and could have surgery as early as Wednesday, sources told ESPN.
European disease control center sends experts to Nigeria while Ebola cases surpass 10,000 in Congo
The European Centre for Disease Prevention and Control (ECDC) deployed a team of experts to Nigeria this week as Ebola spreads across Africa, with cases reported in Kenya and Nigeria, the European agency announced on Tuesday. With the Ebola outbreak continuing to spread beyond the epicentre in the Democratic Republic of Congo — where it surpassed 10,000 cases — ECDC sent a team led by its senior expert in epidemic intelligence to Nigeria, the fourth African country to report an Ebola case....
Day 2 of canceled classes at University of New Mexico after Health Sciences Center cyberattack
The University of New Mexico is canceling classes across the medicine, nursing, and pharmacy faculties for a second day amid continued efforts to recover from a "cybersecurity event. "The attack targeted the Health Sciences Center on Monday, the Uni revealed, forcing it to shut down systems, cancel appointments and clinics at UNM Health hospitals, and divert ambulances to healthcare facilities in nearby Albuquerque and Santa Fe.Hospital appointments and clinics return to normal today,...
GSK to nearly double cancer medicines in clinical trials next year
GSK to nearly double cancer medicines in clinical trials next year LONDON: GSK said on Tuesday (Oct 27) that it expects to almost double the number of cancer medicines it has in clinical trials next year, including those in early-stage studies, as it tries to rebuild its oncology business. The drugmaker's clinical-stage portfolio of about 15 assets would likely "come close to doubling" in 2027, Hesham Abdullah, who heads GSK's oncology research and development, told the Wall Street Journal...